However, combined treatment of XR-2 and NMDi did not increase apoptosis in any of these four TP53-mutated cell lines (Fig. 4C, D, Fig. S3C, D), further confirming that the synergistic effects of XR-2 and NMDi were specific to TP53 wild-type cancer cell lines. The gene discussed is TP53; the disease is cancer.